title: HIV-derived vectors for gene therapy targeting dendritic cells.
abstract: Human immunodeficiency virus type 1 (HIV-1)-derived lentiviral vectors (LV) have the potential to mediate stable therapeutic gene transfer. However, similarly to other viral vectors, their benefit is compromised by the induction of an immune response toward transgene-expressing cells that closely mimics antiviral immunity. LV share with the parental HIV the ability to activate dendritic cells (DC), while lack the peculiar ability of subverting DC functions, which is responsible for HIV immune escape. Understanding the interaction between LV and DC, with plasmacytoid and myeloid DC playing fundamental and distinct roles, has paved the way to novel approaches aimed at regulating transgene-specific immune responses. Thanks to the ability to target either DC subsets LV might be a powerful tool to induce immunity (i.e., gene therapy of cancer), cell death (i.e., in HIV/AIDS infection), or tolerance (i.e., gene therapy strategies for monogenic diseases). In this chapter, similarities and differences between the LV-mediated and HIV-mediated induction of immune responses, with specific focus on their interactions with DC, are discussed.
authors.affiliation: San Raffaele Telethon Institute for Gene Therapy, San Raffaele Scientific Institute, Milan, Italy.
authors.forename: Maura
authors.initials: M
authors.lastname: Rossetti
authors.forename: Mariangela
authors.initials: M
authors.lastname: Cavarelli
authors.forename: Silvia
authors.initials: S
authors.lastname: Gregori
authors.forename: Gabriella
authors.initials: G
authors.lastname: Scarlatti
mesh_terms: D003713:Dendritic Cells / Q000276:immunology*; D015316:Genetic Therapy; D005822:Genetic Vectors; D006678:HIV / Q000235:genetics*; D006801:Humans